Ameliorated pancreatic β cell dysfunction in type 2 diabetic patients treated with a sodium-glucose cotransporter 2 inhibitor ipragliflozin

Endocrine Journal

Volumn 62, Issue 1, 2015, Pages 77-86

  Takahara, Mitsuyoshi ^a   Shiraiwa, Toshihiko ^b   Matsuoka, Taka Aki ^a   Katakami, Naoto ^a   Shimomura, Iichiro ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Shiraiwa Medical Clinic   (Japan)

Author keywords

Disposition index; Ipragliflozin; Sodium glucose cotransporter 2 (SGLT2) inhibitor; Washout; cell function

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; IPRAGLIFLOZIN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLUCOSIDE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2; THIOPHENE DERIVATIVE;

ADULT; ARTICLE; CELL FUNCTION; CLINICAL ARTICLE; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; JAPANESE (PEOPLE); MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PANCREAS DISEASE; PANCREAS ISLET BETA CELL; PANCREATIC BETA CELL DYSFUNCTION; PILOT STUDY; TREATMENT DURATION; TREATMENT OUTCOME; ALGORITHM; ANALYSIS; ANTAGONISTS AND INHIBITORS; BLOOD; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; ETHNOLOGY; GLUCOSE TOLERANCE TEST; HYPERGLYCEMIA; INSULIN RESISTANCE; JAPAN; MIDDLE AGED; PATHOPHYSIOLOGY; SECRETION (PROCESS);

ADULT; ALGORITHMS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE TOLERANCE TEST; GLUCOSIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; JAPAN; MALE; MIDDLE AGED; PILOT PROJECTS; SODIUM-GLUCOSE TRANSPORTER 2; THIOPHENES;

EID: 84922032249     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.EJ14-0335     Document Type: Article

References (35)

1. Leahy JL, Bonner-Weir S, Weir GC (1992) Beta-cell dysfunction induced by chronic hyperglycemia. Current ideas on mechanism of impaired glucose-induced insulin secretion. Diabetes Care 15: 442-455.
2. Rossetti L, Giaccari A, DeFronzo RA (1990) Glucose toxicity. Diabetes Care 13: 610-630.
3. Yki-Jarvinen H (1992) Glucose toxicity. Endocr Rev 13: 415-431.
4. Rossetti L, Shulman GI, Zawalich W, DeFronzo RA (1987) Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. J Clin Invest 80: 1037-1044.
5. Gerich JE (2010) Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med 27: 136-142.
6. Jurczak MJ, Lee HY, Birkenfeld AL, Jornayvaz FR, Frederick DW, et al. (2011) SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. Diabetes 60: 890-898.
7. Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A, et al. (2014) Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 124: 499-508.
8. DeFronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, et al. (2011) Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 364: 1104-1115.
9. Defronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, et al. (2013) Prediction of diabetes based on baseline metabolic characteristics in individuals at high risk. Diabetes Care 36: 3607-3612.
10. Matsuda M, DeFronzo RA (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22: 1462-1470.
11. Pollock NK, Bernard PJ, Gower BA, Gundberg CM, Wenger K, et al. (2011) Lower uncarboxylated osteocalcin concentrations in children with prediabetes is associated with beta-cell function. J Clin Endocrinol Metab 96: E1092-1099.
12. Retnakaran R, Shen S, Hanley AJ, Vuksan V, Hamilton JK, et al. (2008) Hyperbolic relationship between insulin secretion and sensitivity on oral glucose tolerance test. Obesity (Silver Spring) 16: 1901-1907.
13. Utzschneider KM, Prigeon RL, Faulenbach MV, Tong J, Carr DB, et al. (2009) Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. Diabetes Care 32: 335-341.
14. Asano T, Kawamura M, Watanabe T, Abe M, Chin R, et al. (2008) Indices of urinary and serum c-peptide corrected with fasting plasma glucose for decision-making of insulin therapy in type 2 diabetes-validation andcomparison. J Jpn Diabetes Soc 51: 759-763 (in Japanese).
15. Yamada Y, Fukuda K, Fujimoto S, Hosokawa M, Tsukiyama K, et al. (2006) SUIT, secretory units of islets in transplantation: An index for therapeutic management of islet transplanted patients and its application to type 2 diabetes. Diabetes Res Clin Pract 74: 222-226.
16. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, et al. (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53: 982-992.
17. Mari A, Sallas WM, He YL, Watson C, Ligueros-Saylan M, et al. (2005) Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 90: 4888-4894.
18. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, et al. (2006) Effect of the dipeptidyl peptidase- 4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 29: 2632-2637.
19. DeFronzo RA, Hissa MN, Garber AJ, Luiz Gross J, Yuyan Duan R, et al. (2009) The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 32: 1649-1655.
20. Del Prato S, Barnett AH, Huisman H, Neubacher D, Woerle HJ, et al. (2011) Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab 13: 258-267.
21. Bosi E, Ellis GC, Wilson CA, Fleck PR (2011) Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, doubleblind, active-controlled, parallel-group study. Diabetes Obes Metab 13: 1088-1096.
22. Mari A, Nielsen LL, Nanayakkara N, DeFronzo RA, Ferrannini E, et al. (2006) Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea. Horm Metab Res 38: 838-844.
23. Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, et al. (2004) One week’s treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and betacell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 53: 1187-1194.
24. Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, Mari A, et al. (2007) Thiazolidinediones improve betacell function in type 2 diabetic patients. Am J Physiol Endocrinol Metab 292: E871-883.
25. Weng J, Li Y, Xu W, Shi L, Zhang Q, et al. (2008) Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel- group trial. Lancet 371: 1753-1760.
26. Mu PW, Chen YM, Lu HY, Wen XQ, Zhang YH, et al. (2012) Effects of a combination of oral anti-diabetes drugs with basal insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes. Diabetes Metab Res Rev 28: 236-240.
27. Alvarsson M, Sundkvist G, Lager I, Henricsson M, Berntorp K, et al. (2003) Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. Diabetes Care 26: 2231-2237.
28. Hosker JP, Turner RC (1982) Insulin treatment of newly-presenting ketotic diabetic patients into the honeymoon period. Lancet 2: 633-635.
29. Bouche C, Lopez X, Fleischman A, Cypess AM, O’Shea S, et al. (2010) Insulin enhances glucose-stimulated insulin secretion in healthy humans. Proc Natl Acad Sci U S A 107: 4770-4775.
30. Merovci A, Solis-Herrera C, Daniele G, Eldor R, Fiorentino TV, et al. (2014) Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 124: 509-514.
31. Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, et al. (2013) Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol 715: 246-255.
32. Tsuda A, Ishimura E, Ohno Y, Ichii M, Nakatani S, et al. (2014) Poor glycemic control is a major factor in the overestimation of glomerular filtration rate in diabetic patients. Diabetes Care 37: 596-603.
33. Malatiali S, Francis I, Barac-Nieto M (2008) Phlorizin prevents glomerular hyperfiltration but not hypertrophy in diabetic rats. Exp Diabetes Res 2008: 305403.
34. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF (2010) Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 375: 2223-2233.
35. Unger RH (1995) Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes 44: 863-870.